Although immune checkpoint blockade (ICB) demonstrates efficacy in BLCA, therapeutic response is heavily modulated by the metabolic milieu (24, 32).Elevated immune exclusion in high-TMs tumors suggests a physical immune barrier, potentially formed via fibroblast recruitment through the WNT7B–FZD1 axis. Here, FZD1 is linked to bladder transitional cell carcinoma.